Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis

Summary

The purpose of this study is to determine if the study drug is safe, tolerable and active in reducing fluid overload/weight gain between dialysis sessions for patients with End Stage Renal Disease on Hemodialysis.

Timeline

Start

2013-01

Primary completion

2013-10

Completion

2013-10

Outcome

Missed primary endpoint

registry analysis (superiority test); AZD1722 Out-patient vs Placebo Out-patient; p = 0.46; ANCOVA NCT01764854 ↗

Drugs

Indications